U.S. Army Medical Research and Development Command
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, U.S. Army Medical Research and Development Command sits in the top decile of US sponsors by registered trial count (#284 of 15,742 sponsors by registered trial count).
U.S. Army Medical Research and Development Command: 77 sponsored US clinical trials, 3 recruiting.
U.S. Army Medical Research and Development Command sponsors 77 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 71 completed. 0 of these trials are in Phase 3-4 (later-stage) and 70 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Malaria, with 6 trials.
Top-decile sponsor footprint
U.S. Army Medical Research and Development Command ranks in the top decile of sponsors by registered trial count (#284 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
71 of 73 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (97.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
77 total, page 1 of 2
An Evaluation of Two PTSD Assessments in an Active Duty and Military Veteran Sample
NCT04180930
Phase 2 Safety and Immunogenicity Study of Rift Valley Fever Vaccine
NCT03609398
Transcranial Electrical Stimulation (TES) at Slow Oscillation (SO) Frequency During NREM Sleep
NCT02945501
Safety, Tolerability, and Immunogenicity of ALFQ in a HIV Vaccine Containing A244 and B.65321 in Healthy Adults
NCT05423418
Single or Repeat Dose of G03-52-01 in Adult Subjects
NCT05348993
Safety/Immunogenicity Hantaan Virus DNA Vaccine and Puumala Virus DNA Vaccine, For Prevention of HFRS
NCT04333459
Safety and Immunogenicity Study of Venezuelan Equine Encephalomyelitis (VEE) Vaccine as Booster Vaccine in Adults
NCT03531242
PHASE 1 SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19
NCT04784767
Combination HTNV and PUUV DNA Vaccine
NCT03718130
Evaluate the Infectivity Equivalence of Current and New Lots of Plasmodium Falciparum Strain NF54
NCT03882528
Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Malaria Infection in Malaria Naïve Adults
NCT03341754
Study Assessing Pharmacokinetics and Bioavailability of Three Novel Triazine Compounds
NCT03436160
Ascending Doses of Autologous FDP vs FFP
NCT02930226
A Single-blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Hantaan Puumala Virus DNA Vaccine
NCT02776761
Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR)
NCT02445963
Assessment of a Dengue-1-Virus-Live Virus Human Challenge - (DENV-1-LVHC) Virus Strain
NCT02372175
Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults
NCT02421367
TDENV PIV and LAV Dengue Prime-boost Strategy
NCT02239614
Phase 1 Safety Study of Dimethyl Sulfoxide Cryopreserved Platelets
NCT02078284
Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) to Evaluate the Safety and Efficacy of the Plasmodium Falciparum Vaccine Candidate FMP012 Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults
NCT02174978
Phase 2a Immunogenicity Study of Hantaan/Puumala Virus DNA Vaccine for Prevention of Hemorrhagic Fever
NCT02116205
Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea
NCT02067676
Safety and Tolerability of Antiplaque Chewing Gum in a Gingivitis Population
NCT01877421
Immunization Via Mosquito Bite With Radiation-attenuated Sporozoites
NCT01994525
Challenge Study of an ETEC Vaccine
NCT01922856
Safety, Efficacy, and PK of Topical Paromomycin/Gentamicin Cream for Treatment of Cutaneous Leishmaniasis
NCT01140191
Evaluation of CL Detect™ Rapid Test to Detect Cutaneous Leishmaniasis
NCT01865032
Booster Dose (50 µg) of Recombinant Ricin Toxin Vaccine (RVEc™) in Previously Vaccinated Healthy Adults
NCT01846104
mTBI Mechanisms of Action of HBO2 for Persistent Post-Concussive Symptoms
NCT01611194
A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults
NCT01666652
Safety Study of Chimeric Vaccine to Prevent ETEC Diarrhea
NCT01644565
Study to Evaluate the Safety of a New Oxime, MMB4 DIMETHANESULFONATE (DMS)
NCT02018250
Trial of a Falciparum Malaria Protein (FMP012), E. Coli-expressed PfCelTOS, in Healthy Malaria-Naive Adults
NCT01540474
Evaluation of Three Potential Central Nervous System (CNS) Pretreatments for Soman Exposure on Human Performance
NCT01194336
Study to Evaluate the Safety, Tolerability, and Immunogenicity of Hantaan and Puumala Virus DNA Vaccines
NCT01502345
Evaluation of the Safety and the Ability of a DNA Vaccine to Protect Against Dengue Disease
NCT01502358
Safety Study of a Vaccine (DENV-1 PIV) to Prevent Dengue Disease
NCT01502735
Safety Study of Recombinant Vaccine to Prevent ETEC Diarrhea
NCT01382095
Reference Values for Non-invasive Hydration Status Markers H10-14
NCT01387529
Safety and Immunogenicity Study of Recombinant Ricin Toxin A-Chain Vaccine (RVEc™)
NCT01317667
Hyperbaric Oxygen Therapy (HBO2) for Persistent Post-concussive Symptoms After Mild Traumatic Brain Injury (mTBI)
NCT01306968
Study of VMP001 and AS01B (Adjuvant Formulation) in Healthy Malaria-Naïve Adults
NCT01157897
Western Equine Encephalitis Vaccine, Inactivated
NCT01159561
Weekly Dosing of Malarone ® for Prevention of Malaria
NCT00984256
Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated
NCT00869713
Clinical Trial for Malaria Vaccines to Test for Safety, Immune Response and Protection Against Malaria
NCT00870987
Clinical Trial for the Development of a Safe Malaria Challenge Model That Can be Reproduced in Humans
NCT00935623
Merozoite Surface Protein 1 Antibody Response in Asymptomatic Human Malaria Infection
NCT00761020
Safety and Immunogenicity Study of Eastern Equine Encephalitis (EEE) Vaccine
NCT00584805
Safety and Immunogenicity Study of the Eastern Equine Encephalitis (EEE) Vaccine
NCT02654509
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 48 |
| Phase 2 | 22 |
What is open in the U.S. Army Medical Research and Development Command pipeline
3 recruiting of 77 indexed (4% open); 71 completed (92%).
Phase mix: 0 late (III/IV) vs 70 early (I/II) (early-phase heavy).
Top condition: Malaria (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
U.S. Army Medical Research and Development Command: open-pipeline peers nationwide
Peers matched on 77 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
U.S. Army Medical Research and Development Command sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 77 trials (± recruiting share)
- University of Hawaii · 77 trials · 17% recruiting
- RAND · 78 trials · 8% recruiting
- Ionis Pharmaceuticals · 76 trials · 12% recruiting
- MetroHealth Medical Center · 76 trials · 13% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Celgene · 4% recruiting · 308 trials
- MedtronicNeuro · 4% recruiting · 51 trials
- Aldeyra Therapeutics · 4% recruiting · 26 trials
- DexCom · 4% recruiting · 26 trials
Related
What to do with this U.S. Army Medical Research and Development Command page
77 registered trials is a research-attention snapshot, not an endorsement of U.S. Army Medical Research and Development Command or any single study.
- 3 of U.S. Army Medical Research and Development Command's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Malaria is the condition U.S. Army Medical Research and Development Command studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Malaria trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
U.S. Army Medical Research and Development Command pipeline card: 77 registered trials from official public datasets.Report a data error.